Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 24, 2009, Pages 6877-6881

  Lv, Binhua ^a,b,c   Xu, Baihua ^a,b,c   Feng, Yan ^c   Peng, Kun ^c   Xu, Ge ^c   Du, Jiyan ^c   Zhang, Lili ^c   Zhang, Wenbin ^c   Zhang, Ting ^c   Zhu, Liangcheng ^c   Ding, Haifeng ^c   Sheng, Zelin ^c   Welihinda, Ajith ^d   Seed, Brian ^d   Chen, Yuanwei ^a,b,c  

^a CHENGDU INSTITUTE OF ORGANIC CHEMISTRY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Egret Pharma (Shanghai) Limited   (China)

^d Theracos Inc   (United States)

Author keywords

Blood glucose; Glucosuria; O Spiroketal C arylglucosides; SGLT2; Spiro isobenzofuran 1, 2 pyran

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; GLUCOSIDE; PROTEIN INHIBITOR; SERGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLUCOSURIA; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACOPHORE; RAT; RENAL DIABETES; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOFURANS; BLOOD GLUCOSE; GLUCOSIDES; GLYCOSURIA; HUMANS; PYRANS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 2; SPIRO COMPOUNDS;

RATTUS;

EID: 72149090920     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.088     Document Type: Article

References (29)

1. Isaji M. Curr. Opin. Invest. Drugs 8 (2007) 285
2. Wright E.M., Loo D.D., Hirayama B.A., and Turk E. Physiology (Bethesda) 19 (2004) 370
3. Van den Heuvel L.P., Assink K., Willemsen M., and Monnens L. Hum. Genet. 111 (2002) 544
4. Calado J., Loeffler J., Sakallioglu O., Gok F., Lhotta K., Barata J., and Rueff J. Kidney Int. 69 (2006) 852
5. Wright E.M. Am. J. Physiol. 275 (1998) G879
6. Oku A., Ueta K., Arakawa K., Ishihara T., Nawano M., Kuronuma Y., Matsumoto M., Saito A., Tsujihara K., Anai M., Asano T., Kanai Y., and Endou H. Diabetes 48 (1999) 1794
7. Tsujihara K., Hongu M., Saito K., Kawanishi H., Kuriyama K., Matsumoto M., Oku A., Ueta K., Tsuda M., and Saito A. J. Med. Chem. 42 (1999) 5311
8. Washburn W.N. J. Med. Chem. 52 (2009) 1785
9. Katsuno K., Fujimori Y., Takemura Y., Hiratochi M., Itoh F., Komatsu Y., Fujikura H., and Isaji M. J. Pharmacol. Exp. Ther. 320 (2007) 323
10. Fujimori Y., Katsuno K., Nakashima I., Ishikawa-Takemura Y., Fujikura H., and Isaji M. J. Pharmacol. Exp. Ther. 327 (2008) 268
11. Meng W., Ellsworth B.A., Nirschl A.A., McCann P.J., Patel M., Girotra R.N., Wu G., Sher P.M., Morrison E.P., Biller S.A., Zahler R., Deshpande P.P., Pullockaran A., Hagan D.L., Morgan N., Taylor J.R., Obermeier M.T., Humphreys W.G., Khanna A., Discenza L., Robertson J.G., Wang A., Han S., Wetterau J.R., Janovitz E.B., Flint O.P., Whaley J.M., and Washburn W.N. J. Med. Chem. 51 (2008) 1145
12. Gougoutas, J. Z. WO 02/083066; Chem. Abstr. 2002, 137, 311199.
13. Ohsumi K., Matsueda H., Hatanaka T., Hirama R., Umemura T., Oonuki A., Ishida N., Kageyama Y., Maezono K., and Kondo N. Bioorg. Med. Chem. Lett. 13 (2003) 2269
14. Nishimura, T.; Fujikura, H.; Fushimi, N.; Tatani, K.; Katsuno, K.; Isaji, M. WO03/000712; Chem. Abstr. 2003, 138, 49945.
15. Nishimura, T.; Fushimi, N.; Fujikura, H.; Katsuno, K.; Komatsu, Y.; Isaji, M. WO02/068439; Chem. Abstr. 2002, 137, 232854.
16. Washburn, W. N.; Ellsworth, B.; Meng, W.; Wu, G.; Sher, P. M. US03/0114390; Chem. Abstr. 2003, 139, 36736.
17. Kobayashi, T.; Sato, T.; Nishimoto, M. WO 2006/080421; Chem. Abstr. 2006, 145, 189115.
18. Xu, B.; Lv, B.; Feng, Y.; Xu, G.; Du, J.; Welihinda, A.; Sheng, Z.; Seed, B.; Chen, Y., unpublished results.
19. Horton D., and Priebe W. Carbohydr. Res. 94 (1981) 27
20. Deshpande, P. P.; Ellsworth, B. A.; Singh, J.; Denzel, T. W.; Lai, C.; Crispino, G.; Randazzo, M. E.; Gougoutas, J. Z. WO2004/063209; Chem. Abstr. 2004, 141, 89317.
21. Argentini M., Wiese C., and Weinreich R. J. Fluorine Chem. 68 (1994) 141
22. Czernecki S., and Ville G. J. Org. Chem. 54 (1989) 610
23. 1 HNMR, LC-MS). The detailed synthetic procedure for each compound can be found in Chen, Y.; Feng, Y.; Xu, B.; Lv, B.; Dong, J.; Seed, B.; Hadd, M. J. US 2007/0275907; Chem. Abstr. 2007, 147, 542063.
24. Mark, L. R.; Charles, J. M.; Chyall, L. J.; Paul, K. WO 2000020364; Chem. Abstr. 2002, 132, 265874.
25. Lorenz J.C., Long J., Yang Z., Xue S., Xie Y., and Shi Y. J. Org. Chem. 69 (2004) 327
26. 50 calculations were performed using nonlinear regression with variable slope. As a reference standard, a derivative of dapagliflozin was routinely included in the assays. In 26 independent evaluations, the reference compound inhibited SGLT2 activity by 69.7 ± 9.6% and SGLT1 by 72.7 ± 6.7% at 10 nM and 10 μM, respectively.
27. Zhou L., Cryan E.V., D'Andrea M.R., Belkowski S., Conway B.R., and Demarest K.T. J. Cell. Biochem. 90 (2003) 339
28. Pascual J.M., Wang D., Lecumberri B., Yang H., Mao X., Yang R., and De Vivo D.C. Eur. J. Endocrinol. 150 (2004) 627
29. Ellsworth B.E., Meng W., Patel M., Girotra R.N., Wu G., Sher P., Hagan D., Obermeier M., Humphreys W.G., Robertson J.G., Wang A., Han S., Waldron T., Morgan N.N., Whaley J.M., and Washburn W.N. Bioorg. Med. Chem. Lett. 18 (2008) 4770